Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Takhzyro (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and older.
• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Lanadelumab (300 mg every 2 or 4 weeks) demonstrated statistically significant effectiveness over berotralstat (150 mg or 110 mg once daily) in reducing hereditary angioedema (HAE) attack rates per 28 days and achieving a ≥90% reduction in monthly HAE attacks.
• All drugs except avoralstat were effective in reducing the number of HAE attacks compared to placebo, with lanadelumab and various forms of C1-INH notably effective in reducing the severity of breakthrough attacks. Quality of life improvements were observed for avoralstat, berotralstat, C1-INH (all forms), and lanadelumab compared to placebo.
• The findings apply to individuals with Type I and II HAE, with no data available for Type III HAE. The effectiveness of lanadelumab and C1-INH in reducing the severity of breakthrough attacks was highlighted, but data on other drugs for this outcome were lacking.
• In the systematic review, adverse events, including serious adverse events, occurred at rates comparable to placebo for all drugs studied (avoralstat, berotralstat, subcutaneous C1-INH, plasma-derived C1-INH, nanofiltered C1-INH, recombinant human C1-INH, danazol, and lanadelumab). Specific serious adverse events included hepatic dysfunction, hepatic toxicity, and deleterious changes in blood tests; however, data for danazol were insufficient for conclusive safety assessment.
• No deaths were reported in any of the studies included in the systematic review.
• There is no population type or subgroup information available in the reviewed studies.